Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R, and Lactobacillus rhamnosus CLR2 (Bio-K+): Characterization, manufacture, mechanisms of action, and quality control of a specific probiotic combination for primary prevention of clostridium difficile infection

Clinical Infectious Diseases

Volumn 60, Issue , 2015, Pages S135-S143

  Auclair, Julie ^a   Frappier, Martin ^a   Millette, Mathieu ^a  

^a Bio K+ International Inc   (Canada)

Author keywords

Bio K+; Clostridium difficile; Lactobacillus; prevention; probiotic

Indexed keywords

CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; LACTIC ACID; PROBIOTIC AGENT; RNA 16S;

ANTIBIOTIC ASSOCIATED DIARRHEA; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIAL SURVIVAL; BEVERAGE; CACO 2 CELL LINE; CELL STRUCTURE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; CYTOTOXICITY; DRUG MANUFACTURE; DRUG MECHANISM; FERMENTED PRODUCT; GROWTH INHIBITION; HT 29 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; INCIDENCE; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS CASEI; LACTOBACILLUS RHAMNOSUS; MICROCAPSULE; PRIMARY PREVENTION; PRIORITY JOURNAL; QUALITY CONTROL; SHELF LIFE; CLOSTRIDIUM INFECTIONS; DIARRHEA; ISOLATION AND PURIFICATION; MICROBIOLOGY; NORTH AMERICA; PEPTOCLOSTRIDIUM DIFFICILE; STANDARDS;

CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; DIARRHEA; HUMANS; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS CASEI; LACTOBACILLUS RHAMNOSUS; NORTH AMERICA; PRIMARY PREVENTION; PROBIOTICS; QUALITY CONTROL;

EID: 84928885373     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ179     Document Type: Article

References (64)

1. The Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature 2012; 486: 207-14.
2. Le Chatelier E, Nielsen T, Qin J, et al. Richness of human gut microbiome correlates with metabolic markers. Nature 2013; 500: 541-6.
3. Lawley TD, Walker AW. Intestinal colonization resistance. Immunology 2013; 138: 1-11.
4. Buffie CG, Pamer EG. Microbiota-mediated colonization resistance against intestinal pathogens. Nat Rev Immunol 2013; 13: 790-801.
5. Britton RA, Young VB. Role of the intestinal microbiota in resistance to colonization by Clostridium difficile. Gastroenterology 2014; 146: 1547-53.
6. Dethlefsen L, Huse S, Sogin ML, Relman DA. The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLoS Biol 2008; 6: e280.
7. Dethlefsen L, Relman DA. Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc Natl Acad Sci U S A 2011; 108(suppl 1): 4554-61.
8. Knecht H, Neulinger SC, Heinsen FA, et al. Effects of beta-lactam antibiotics and fluoroquinolones on human gut microbiota in relation to Clostridium difficile associated diarrhea. PLoS One 2014; 9: e89417.
9. Bignardi GE. Risk factors for Clostridium difficile infection. J Hosp Infect 1998; 40: 1-15.
10. Vassallo A, Tran MC, Goldstein EJ. Clostridium difficile: improving the prevention paradigm in healthcare settings. Expert Rev Anti Infect Ther 2014; 12: 1087-102.
11. Vonberg RP, Kuijper EJ, Wilcox MH, et al. Infection control measures to limit the spread of Clostridium difficile. Clin Microbiol Infect 2008; 14(suppl 5): 2-20.
12. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31: 431-55.
13. Talpaert MJ, Gopal Rao G, Cooper BS, Wade P. Impact of guidelines and enhanced antibiotic stewardship on reducing broad-spectrum antibiotic usage and its effect on incidence of Clostridium difficile infection. J Antimicrob Chemother 2011; 66: 2168-74.
14. Curtin BF, Zarbalian Y, Flasar MH, von Rosenvinge E. Clostridium difficile-associated disease: adherence with current guidelines at a tertiary medical center. World J Gastroenterol 2013; 19: 8647-51.
15. Martin M, ZinggW, Knoll E, Wilson C, Dettenkofer M. National European guidelines for the prevention of Clostridium difficile infection: a systematic qualitative review. J Hosp Infect 2014; 87: 212-9.
16. Chitnis AS, Holzbauer SM, Belflower RM, et al. Epidemiology of community-associated Clostridium difficile infection, 2009 through 2011. JAMA Intern Med 2013; 173: 1359-67.
17. Food and Agriculture Organization/World Health Organization. Report of a joint FAO/WHO expert consultation on evaluation of health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria. Cordoba, Argentina: FAO/WHO, 2001.
18. Hill C, Guarner F, Reid G, et al. Expert consensus document: the International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol 2014; 11: 506-14.
19. Gibson MK, Pesesky MW, Dantas G. The yin and yang of bacterial resilience in the human gut microbiota. J Mol Biol 2014; 426: 3866-76.
20. Wolvers D, Antoine JM, Myllyluoma E, Schrezenmeir J, Szajewska H, Rijkers GT. Guidance for substantiating the evidence for beneficial effects of probiotics: prevention and management of infections by probiotics. J Nutr 2010; 140: 698S-712.
21. Ouwehand AC, DongLian C, Weijian X, et al. Probiotics reduce symptoms of antibiotic use in a hospital setting: a randomized dose response study. Vaccine 2014; 32: 458-63.
22. Hempel S, Newberry SJ, Maher AR, et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. JAMA 2012; 307: 1959-69.
23. Videlock EJ, Cremonini F. Meta-analysis: probiotics in antibiotic-associated diarrhoea. Aliment Pharmacol Ther 2012; 35: 1355-69.
24. Johnson S, Maziade PJ, McFarland LV, et al. Is primary prevention of Clostridium difficile infection possible with specific probiotics? Int J Infect Dis 2012; 16: e786-92.
25. Beausoleil M, Fortier N, Guenette S, et al. Effect of a fermented milk combining Lactobacillus acidophilus Cl1285 and Lactobacillus casei in the prevention of antibiotic-associated diarrhea: a randomized, double-blind, placebo-controlled trial. Can J Gastroenterol 2007; 21: 732-6.
26. Sampalis J, Psaradellis E, Rampakakis E. Efficacy of BIO K+ CL1285 in the reduction of antibiotic-associated diarrhea-a placebo controlled double-blind randomized, multi-center study. Arch Med Sci 2010; 6: 56-64.
27. Gao XW, Mubasher M, Fang CY, Reifer C, Miller LE. Dose-response efficacy of a proprietary probiotic formula of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R for antibiotic-associated diarrhea and Clostridium difficile-associated diarrhea prophylaxis in adult patients. Am J Gastroenterol 2010; 105: 1636-41.
28. Maziade PJ, Andriessen JA, Pereira P, Currie B, Goldstein EJ. Impact of adding prophylactic probiotics to a bundle of standard preventative measures for Clostridium difficile infections: enhanced and sustained decrease in the incidence and severity of infection at a community hospital. Curr Med Res Opin 2013; 29: 1341-7.
29. Anonymous. Natural health product-probiotics. Natural Health Food Directorate. Health Canada, 2014: pp. 1-25. Available at: http://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq.do?atid=probio. Accessed 16 March 2015.
30. Anonymous. Guidance document-the use of probiotic microorganisms in food. Food Directorate, Health Products and Food Branch. Health Canada, 2009: pp. 1-8. Available at: http://www.hc-sc.gc.ca/fnan/legislation/guide-ld/probiotics-guidance-orientation-probiotiqueseng.php. Accessed 16 March 2015.
31. Kwon HS, Yang EH, Yeon SW, Kang BH, Kim TY. Rapid identification of probiotic Lactobacillus species by multiplex PCR using species-specific primers based on the region extending from 16S rRNA through 23S rRNA. FEMS Microbiol Lett 2004; 239: 267-75.
32. Ward LJ, Timmins MJ. Differentiation of Lactobacillus casei, Lactobacillus paracasei and Lactobacillus rhamnosus by polymerase chain reaction. Lett Appl Microbiol 1999; 29: 90-2.
33. Pattani R, Palda VA, Hwang SW, Shah PS. Probiotics for the prevention of antibiotic-associated diarrhea and Clostridium difficile infection among hospitalized patients: systematic review and meta-analysis. Open Med 2013; 7: e56-67.
34. Azais-Braesco V, Bresson JL, Guarner F, Corthier G. Not all lactic acid bacteria are probiotics, . . . but some are. Br J Nutr 2010; 103: 1079-81.
35. Grzeskowiak L, Isolauri E, Salminen S, Gueimonde M. Manufacturing process influences properties of probiotic bacteria. Br J Nutr 2011; 105: 887-94.
36. Nivoliez A, Camares O, Paquet-GachinatM, Bornes S, Forestier C, Veisseire P. Influence of manufacturing processes on in vitro properties of the probiotic strain Lactobacillus rhamnosus Lcr35. J Biotechnol 2012; 160: 236-41.
37. Béal C, Marin M, Fontaine É, Fonseca F, Obert J-P. Production et conservation des ferments lactiques et probiotiques. In: Georges C, Luquet F-M, eds. Bactéries lactiques-De la génétique aux ferments. Paris: Éditions Tec & Doc, 2008: 661-786.
38. Sanders ME, Klaenhammer TR, Ouwehand AC, et al. Effects of genetic, processing, or product formulation changes on efficacy and safety of probiotics. Ann N Y Acad Sci 2014; 1309: 1-18.
39. Gueimonde M, Sanchez B. Enhancing probiotic stability in industrial processes. Microb Ecol Health Dis 2012; 23: 18562.
40. Forssten SD, SindelarCW, Ouwehand AC. Probiotics from an industrial perspective. Anaerobe 2011; 17: 410-3.
41. Elliot E, Teversham K. An evaluation of nine probiotics available in South Africa, August 2003. S Afr Med J 2004; 94: 121-4.
42. Drisko J, Bischoff B, Giles C, Adelson M, Rao RV, McCallum R. Evaluation of five probiotic products for label claims by DNA extraction and polymerase chain reaction analysis. Dig Dis Sci 2005; 50: 1113-7.
43. Weese JS, Martin H. Assessment of commercial probiotic bacterial contents and label accuracy. Can Vet J 2011; 52: 43-6.
44. Goldstein EJ, Citron DM, Claros MC, Tyrrell KL. Bacterial counts from five over-the-counter probiotics: are you getting what you paid for? Anaerobe 2014; 25: 1-4.
45. Ben Amor K, Vaughan EE, de VosWM. Advancedmolecular tools for the identification of lactic acid bacteria. J Nutr 2007; 137(3 Suppl 2): 741S-7.
46. Herbel SR, Vahjen W, Wieler LH, Guenther S. Timely approaches to identify probiotic species of the genus Lactobacillus. Gut Pathog 2013; 5: 27.
47. Edwards U, Rogall T, Blocker H, Emde M, Bottger EC. Isolation and direct complete nucleotide determination of entire genes. Characterization of a gene coding for 16S ribosomal RNA. Nucleic Acids Res 1989; 17: 7843-53.
48. Versalovic J, Schneider M, de Bruijn FJ, Lupski JR. Genomic fingerprinting of bacteria using repetitive sequence-based polymerase chain reaction. Methods Mol Cell Biol 1994; 5: 25-40.
49. Anonymous. Quality of Natural Health Products Guide. Natural Health Products Directorate. Health Canada, 2012: pp. 1-44. Available at: http://www.hc-sc.gc.ca/dhp-mps/prodnatur/legislation/docs/eq-paqeng. php. Accessed 16 March 2015.
50. Bosnea LA, Kourkoutas Y, Albantaki N, Tzia C, Koutinas AA, Kanellaki M. Functionality of freeze-dried L. casei cells immobilized on wheat grains. LWT-Food Sci Technol 2009; 42: 1696-702.
51. Pitino I, Randazzo CL, Mandalari G, et al. Survival of Lactobacillus rhamnosus strains in the upper gastrointestinal tract. Food Microbiol 2010; 27: 1121-7.
52. Charteris WP, Kelly PM, Morelli L, Collins JK. Development and application of an in vitro methodology to determine the transit tolerance of potentially probiotic Lactobacillus and Bifidobacterium species in the upper human gastrointestinal tract. J Appl Microbiol 1998; 84: 759-68.
53. de los Reyes-Gavilan CG, Suarez A, Fernandez-Garcia M, Margolles A, Gueimonde M, Ruas-Madiedo P. Adhesion of bile-adapted Bifidobacterium strains to the HT29-MTX cell line is modified after sequential gastrointestinal challenge simulated in vitro using human gastric and duodenal juices. Res Microbiol 2011; 162: 514-9.
54. Lo Curto A, Pitino I, Mandalari G, Dainty JR, Faulks RM, John Wickham MS. Survival of probiotic lactobacilli in the upper gastrointestinal tract using an in vitro gastric model of digestion. Food Microbiol 2011; 28: 1359-66.
55. Mainville I, Arcand Y, Farnworth ER. A dynamic model that simulates the human upper gastrointestinal tract for the study of probiotics. Int J Food Microbiol 2005; 99: 287-96.
56. Sumeri I, Arike L, Adamberg K, Paalme T. Single bioreactor gastrointestinal tract simulator for study of survival of probiotic bacteria. Appl Microbiol Biotechnol 2008; 80: 317-24.
57. Millette M, Nguyen A, Amine KM, Lacroix M. Gastrointestinal survival of bacteria in commercial probiotic products. Int J Probiotics Prebiotics 2013; 8: 149-56.
58. Marteau P, Seksik P. Probiotiques et alicaments. In: Luquet F-M, Corrieu G, eds. Bactéries lactiques et probiotiques. Paris: Editions Tec & Doc, 2005: 255-90.
59. Karska-Wysocki B, Bazo M, Smoragiewicz W. Antibacterial activity of Lactobacillus acidophilus and Lactobacillus casei against methicillin-resistant Staphylococcus aureus (MRSA). Microbiol Res 2010; 165: 674-86.
60. Millette M, Luquet FM, Lacroix M. In vitro growth control of selected pathogens by Lactobacillus acidophilus-and Lactobacillus casei-fermented milk. Lett Appl Microbiol 2007; 44: 314-9.
61. Schillinger U, Lucke FK. Antibacterial activity of Lactobacillus sake isolated from meat. Appl Environ Microbiol 1989; 55: 1901-6.
62. Millette M, Cornut G, Dupont C, Shareck F, Archambault D, Lacroix M. Capacity of human nisin-and pediocin-producing lactic acid bacteria to reduce intestinal colonization by vancomycin-resistant enterococci. Appl Environ Microbiol 2008; 74: 1997-2003.
63. Castagliuolo I, Riegler MF, Valenick L, LaMont JT, Pothoulakis C. Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa. Infect Immun 1999; 67: 302-7.
64. Qa'Dan M, Spyres LM, Ballard JD. pH-induced conformational changes in Clostridium difficile toxin B. Infect Immun 2000; 68: 2470-4.